Loading
A phase 1/2 trial of MK-1045 in non-hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) is a phase 1/2 interventional study registered as NCT07519772 by Merck Sharp & Dohme LLC, with 280 participants planned, started 2026-05-03 and due to reach its primary completion in 2030-07-01. Interventions recorded: MK-1045. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares MK-1045, Merck & Co. (MSD).
Shares MK-1045, Merck & Co. (MSD).
Shares MK-1045, Merck & Co. (MSD).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/